Literature DB >> 1317259

Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.

Y Pommier1, A Orr, K W Kohn, J F Riou.   

Abstract

Amsacrine and demethylepipodophyllotoxins (etoposide and teniposide) are potent topoisomerase II inhibitors which have optimum activity in different cancers. To investigate whether these differences are due to different activity on cellular oncogenes, drug-induced topoisomerase II cleavage sites were mapped and sequenced in the human c-myc protooncogene. In the presence of purified murine L1210 topoisomerase II, amsacrine induces prominent cleavage in the P2 promoter (site 2499/2502). Footprinting experiments indicate that topoisomerase II binds to the entire promoter region (approximately 20 base pairs on the sides of the P2 site). In the case of teniposide or etoposide, cleavage is more diffuse and markedly less at the P2 site. Mapping of cleavage sites in human small cell lung carcinoma cells (NCI N417) also shows that cleavage in the P2 promoter region is induced preferentially by amsacrine but not by demethylepipodophyllotoxins. Thus, selective gene damage among topoisomerase II inhibitors may contribute to differential anticancer activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1317259

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Distribution of topoisomerase II-mediated cleavage sites and relation to structural and functional landmarks in 830 kb of Drosophila DNA.

Authors:  R Miassod; S V Razin; R Hancock
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

2.  Transcriptional consequences of topoisomerase inhibition.

Authors:  I Collins; A Weber; D Levens
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

3.  Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.

Authors:  I I Gromova; B Thomsen; S V Razin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

4.  Loss of drug-stimulated topoisomerase II DNA breaks in living cells is different at two unrelated loci.

Authors:  M Binaschi; M E Borgnetto; G Capranico
Journal:  Nucleic Acids Res       Date:  2000-09-01       Impact factor: 16.971

5.  TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.

Authors:  Edgar Gonzalez-Buendia; Junfei Zhao; Lu Wang; Subhas Mukherjee; Daniel Zhang; Víctor A Arrieta; Eric Feldstein; J Robert Kane; Seong Jae Kang; Catalina Lee-Chang; Aayushi Mahajan; Li Chen; Ronald Realubit; Charles Karan; Lisa Magnuson; Craig Horbinski; Stacy A Marshall; Jann N Sarkaria; Ahmed Mohyeldin; Ichiro Nakano; Mukesh Bansal; Charles D James; Daniel J Brat; Atique Ahmed; Peter Canoll; Raul Rabadan; Ali Shilatifard; Adam M Sonabend
Journal:  Clin Cancer Res       Date:  2021-08-25       Impact factor: 12.531

Review 6.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

7.  DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.

Authors:  D W Russell; I E Alexander; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

8.  Role of minor groove width and hydration pattern on amsacrine interaction with DNA.

Authors:  Deepak K Jangir; Suman Kundu; Ranjana Mehrotra
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.